Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

id: 351130
Source ↗ · id

opportunityNumber: FOR-FD-24-007
Source ↗ · opportunityNumber

opportunityTitle: Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed
Source ↗ · opportunityTitle

revision: 1
Source ↗ · revision

agencyDetails: {"code":"FDA","seed":"HHS-FDA","agencyName":"Food and Drug Administration","agencyCode":"HHS-FDA","topAgencyCode":"HHS"}
Source ↗ · agencyDetails

owningAgencyCode: HHS-FDA
Source ↗ · owningAgencyCode

cfdas: [{"id":415638,"opportunityId":351130,"cfdaNumber":"93.103","programTitle":"Food and Drug Administration Research"}]
Source ↗ · cfdas

forecastDesc: <p><span style="color: black;">The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.&nbsp;</span></p>
Source ↗ · forecastDesc

applicantTypes: [{"id":"12","description":"Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"01","description":"County governments"},{"id":"05","description":"Independent school districts"},{"id":"20","description":"Private institutions of higher education"},{"id":"06","description":"Public and State controlled institutions of higher education"},{"id":"00","description":"State governments"},{"id":"11","description":"Native American tribal organizations (other than Federally recognized tribal governments)"},{"id":"02","description":"City or township governments"},{"id":"25","description":"Others (see text field entitled \"Additional Information on Eligibility\" for clarification)"},{"id":"07","description":"Native American tribal governments (Federally recognized)"},{"id":"13","description":"Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"99","description":"Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled \"Additional Information on Eligibility\""},{"id":"22","description":"For profit organizations other than small businesses"},{"id":"08","description":"Public housing authorities/Indian housing authorities"},{"id":"04","description":"Special district governments"},{"id":"23","description":"Small businesses"}]
Source ↗ · applicantTypes

applicantEligibilityDesc: Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:&bull;A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.&bull;A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.&bull;An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Source ↗ · applicantEligibilityDesc

fundingInstruments: [{"id":"CA","description":"Cooperative Agreement"}]
Source ↗ · fundingInstruments

fundingActivityCategories: [{"id":"AG","description":"Agriculture"},{"id":"CP","description":"Consumer Protection"},{"id":"FN","description":"Food and Nutrition"}]
Source ↗ · fundingActivityCategories

awardFloor: 300000
Source ↗ · awardFloor

awardCeiling: 300000
Source ↗ · awardCeiling

costSharing: false
Source ↗ · costSharing

lastUpdatedDate: Nov 30, 2023 04:01:41 PM EST
Source ↗ · lastUpdatedDate

status: forecasted
Source ↗ · oppHits[id=351130].oppStatus